Summary
Myelodysplastic syndromes (MDS) are myeloid malignancies most commonly diagnosed at an advanced age. They are considered a spectrum of malignancies that can range from low to high grade and they are classified based on an international prognostic system. This prognostic system separates them into a range from very low risk with survival rates of several years to very high risk with survival rates of less than a year. Therapeutic interventions have focused on targeting higher risk MDS (from intermediate to very high risk), as the benefit of disease-modifying therapies far outweighs the risk of
